文献速递外周动脉疾病

生物可吸收血管支架治疗膝下动脉病变的单臂系统评价与荟萃分析

Efficacy of Bioresorbable Vascular Scaffolds in Below-the-Knee Arterial Disease: A Single-Arm Systematic Review and Meta-Analysis.
PubMed 文献 · Ann Vasc Surg · 2026-01-05

汇总1年通畅率为90%(95%CI 0.85-0.95),免于靶病变血运重建率为94%(95%CI 0.92-0.96),临床缓解率为83%(95%CI 0.79-0.86),围术期并发症率3%、1年死亡率9%。作者认为BVS短期安全有效,但证据质量低,结果应视为探索性。

要点

  • BVS治疗膝下动脉病变1年通畅率90%、免于TLR率94%、临床缓解率83%。
  • 围术期并发症率3%,1年死亡率9%,短期安全性可接受。
  • 证据多来自小样本非随机研究,结果仅作探索性参考。

核心结论

  • BVS在膝下动脉血运重建中显示出良好的短期安全性和疗效。
  • 因缺乏对照数据且多为小型非随机研究,结果应视为探索性。
  • 需更大规模随机对照试验及长期随访验证。

研究设计与样本

  • 纳入研究的平均病变长度范围为20.1 mm至43.8 mm。
  • 根据异质性采用随机或固定效应模型。

主要发现

  • 汇总1年通畅率为90%(95%CI 0.85-0.95,I2=63.8%)。
  • 汇总免于靶病变血运重建(TLR)率为94%(95%CI 0.92-0.96,I2=0.0%)。
  • 汇总临床缓解率为83%(95%CI 0.79-0.86,I2=0.0%)。
  • 汇总围术期并发症率为3%,1年死亡率为9%。
  • 敏感性分析证实汇总估计稳健,但通畅率异质性仍为中等。

临床怎么用

  • 对于膝下动脉病变,BVS可作为短期血管支撑的探索性选择。
  • 现有证据不足以确立BVS在膝下动脉疾病中的标准治疗地位,需个体化决策。
  • 临床应关注长期通畅性和安全性,优先考虑参与随机对照试验。

局限性

  • 单臂荟萃分析缺乏对照数据,无法与球囊血管成形术或金属支架直接比较。
  • 纳入研究多为小型非随机设计,整体证据质量低。
  • 通畅率存在中等异质性,可能影响汇总结果的解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Below-the-knee (BTK) lesions in peripheral artery disease (PAD) are associated with high restenosis rates and poor limb outcomes. Bioresorbable vascular scaffolds (BVS) have emerged as temporary vessel support that may overcome the limitations of balloon angioplasty and metallic stents. However, their efficacy and safety in BTK revascularization remain uncertain. METHODS: A systematic review and single-arm meta-analysis were performed by searching PubMed, Embase, Cochrane Library, Web of Science, and Scopus from inception to October 2025. Studies reporting at least 1-year outcomes after BVS implantation in BTK lesions were included. Primary efficacy end points were 1-year patency, freedom from target lesion revascularization (TLR), and clinical remission; safety end points included all-cause mortality and perioperative complications. Random- or fixed-effects models were applied according to heterogeneity. RESULTS: Eleven studies with 591 patients were included (1 randomized, 3 prospectives, 6 retrospectives, and 1 conference abstract). The average lesion length across included studies ranged from 20.1 mm to 43.8 mm. The pooled 1-year patency, freedom from TLR, and clinical remission rates were 90% (95% confidence interval (CI): 0.85-0.95, I2 = 63.8%), 94% (95% CI: 0.92-0.96, I2 = 0.0%), and 83% (95% CI: 0.79-0.86, I2 = 0.0%), respectively. The pooled perioperative complication and 1-year mortality rates were 3% and 9%. Sensitivity analysis confirmed the robustness of pooled estimates, while heterogeneity remained moderate for patency. The overall quality of evidence was low due to the observational design of most studies. CONCLUSION: BVS demonstrate favorable short-term safety and efficacy in BTK revascularization. However, as this single-arm meta-analysis lacks comparator data and includes mostly small, nonrandomized studies, the results should be interpreted as exploratory. Larger, randomized controlled trials with long-term follow-up are warranted to validate these findings and define the role of BVS in BTK arterial disease.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Cui HJ, Li ML, Wu YF, et al. Efficacy of Bioresorbable Vascular Scaffolds in Below-the-Knee Arterial Disease: A Single-Arm Systematic Review and Meta-Analysis. Ann Vasc Surg. 2026. PMID: 41500331. doi:10.1016/j.avsg.2025.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。